Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $49.00

Syndax Pharmaceuticals (NASDAQ:SNDX) had its price objective lifted by HC Wainwright from $47.00 to $49.00 in a report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

SNDX has been the subject of a number of other reports. Stifel Nicolaus lifted their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Barclays lifted their target price on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. The Goldman Sachs Group boosted their price objective on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. Bank of America boosted their price objective on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the stock a “buy” rating in a research report on Thursday, August 15th. Finally, JPMorgan Chase & Co. reduced their price objective on Syndax Pharmaceuticals from $34.00 to $33.00 and set an “overweight” rating for the company in a research report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

Syndax Pharmaceuticals Stock Up 1.0 %

Shares of SNDX stock opened at $16.79 on Tuesday. The company’s 50-day simple moving average is $18.99 and its 200-day simple moving average is $20.27. Syndax Pharmaceuticals has a one year low of $14.50 and a one year high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the previous year, the firm earned ($0.73) earnings per share. Sell-side analysts predict that Syndax Pharmaceuticals will post -3.61 earnings per share for the current year.

Institutional Trading of Syndax Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Swiss National Bank lifted its holdings in Syndax Pharmaceuticals by 5.8% in the first quarter. Swiss National Bank now owns 150,600 shares of the company’s stock valued at $3,584,000 after buying an additional 8,200 shares during the period. Sei Investments Co. raised its holdings in shares of Syndax Pharmaceuticals by 2.5% during the first quarter. Sei Investments Co. now owns 40,463 shares of the company’s stock worth $963,000 after acquiring an additional 991 shares during the period. ProShare Advisors LLC raised its holdings in shares of Syndax Pharmaceuticals by 29.6% during the first quarter. ProShare Advisors LLC now owns 20,112 shares of the company’s stock worth $479,000 after acquiring an additional 4,599 shares during the period. Vanguard Group Inc. raised its holdings in shares of Syndax Pharmaceuticals by 13.6% during the first quarter. Vanguard Group Inc. now owns 4,926,984 shares of the company’s stock worth $117,262,000 after acquiring an additional 591,631 shares during the period. Finally, Ameritas Investment Partners Inc. raised its holdings in shares of Syndax Pharmaceuticals by 20.0% during the first quarter. Ameritas Investment Partners Inc. now owns 7,858 shares of the company’s stock worth $187,000 after acquiring an additional 1,312 shares during the period.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).